CN1399976A - Chinese medicine powder preparation for resisting thrombosis and its preparation method - Google Patents
Chinese medicine powder preparation for resisting thrombosis and its preparation method Download PDFInfo
- Publication number
- CN1399976A CN1399976A CN 01123530 CN01123530A CN1399976A CN 1399976 A CN1399976 A CN 1399976A CN 01123530 CN01123530 CN 01123530 CN 01123530 A CN01123530 A CN 01123530A CN 1399976 A CN1399976 A CN 1399976A
- Authority
- CN
- China
- Prior art keywords
- powder
- preparation
- extract
- add
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a Chinese medicine powder preparation for resisting thrombosis and its preparation method. It is composed of (wt%) 13-15% of leech powder, 13-15% of venin microcrystal cellulose inclusion, 10-12.5% or red ganoderma carposporophyte fine pwoder, 7.5-10% of astragalus root fine powder, 25-27% of two tea fine powder and 25-27% of gynostemma pentaphylla fine powder through a certain preparation process. Said ivnented medicine possesses the actions of reducing fibrinogen, reducing blood viscousity, depolymerizing, dissolving thrombosis, expanding vessel and improving microcirculation, and has obvious therapeutic effect for curing cerebral thrombosis, cerebral ischemia attack, coronary heart disease, angine pectors, cardiac infarction and others.
Description
The present invention relates to a kind of antithrombotic Chinese powder medicine and preparation method thereof, belong to the new drug technology of preparing.
Cerebral embolism, millions of person-times of the annual morbidities in the whole nation, mortality rate and disability rate all account for the front three of morbidity statistics, threaten very serious to human beings'health.
Motherland's medical science is early on the books to thrombotic disease, is called " hitting the servant " and " estimating partially " in " interior warp ", is called in " Medical Treasures of the Golden Chamber " " apoplexy ", and in the Chinese medicine evolution of two thousand years, has accumulated valuable treatment experience.
The inventor was through the research in 17 years, on the experiential basis of summing up the Chinese medicine thrombotic disease, the advanced theory and technology of utilization modern medicine, the Chinese powder medicine of developing a kind of effective treatment cerebral thrombosis, cerebral blood supply insufficiency, coronary heart disease, myocardial infarction, angina pectoris, vasculitis, the contour sticking mass formed by blood stasis of phlebothrombosis of success, and diabetes and complication are also had curative effect preferably.
The objective of the invention is: a kind of antithrombotic Chinese powder medicine and preparation method thereof is provided, reaches effective treatment cerebral embolism, cerebral blood supply insufficiency, coronary heart disease, myocardial infarction, angina pectoris, vasculitis, the contour sticking mass formed by blood stasis of phlebothrombosis.
A kind of antithrombotic Chinese powder medicine of the present invention is made up of the Chinese medicine scientific matching: (percentage by weight)
Hirudo powder 13-15%
Snake venom microcrystalline Cellulose clathrate (wherein contain respectively is agkistrodon halyx pallas venom and the cobra venom of the 3-5/10000 of total amount) 13-15%
The smart powder 10-12.5% of red ganoderma sporophore
Radix Astragali essenc powder 7.5-10%
The smart powder 25-27% of Tuo tea
Strand Lenzin powder 25-27%
The preparation method of the pure Chinese powder medicine of the present invention is:
A. will give birth to the drying in the sun Hirudo and wear into fine powder;
B. agkistrodon halyx pallas venom, cobra venom and microcrystalline cellulose medicine are ground jointly, make the enclose powder;
C. with the red ganoderma sporophore, at 90-100 ℃, two atmospheric pressure extract extract following minute three times, and 3 hours for the first time, 2 hours for the second time, 1 hour for the third time, add the water of 10 times of doses at every turn, add a small amount of dextran powder then and extract smart powder.
D. with the Radix Astragali, Tuo tea, Herb Gynostemmae Pentaphylli respectively at 90-100 ℃, following minute second extraction extract of two atmospheric pressure, 2 hours for the first time, 1 hour for the second time, add the water of 10 times of doses at every turn, add a small amount of dextran powder then and extract smart powder.
A kind of antithrombotic Chinese powder medicine of the present invention is made up of principal agent, adjuvant, adjuvant drug.
Principal agent: Hirudo, snake venom one removing blood stasis, the meridian dredging that dispels the wind, anticoagulant and thrombolytic
Hirudo: flat, salty, bitter, poisonous; To return Liver Channel, function be removing blood stasis, removing blood stasis, stimulate the menstrual flow, Hirudo contains hirudin, heparin, antithrombotic element, can effectively stop prothrombing to fibrinogenic effect, thus the thrombosis of control.Hirudo single decoct can reduce whole blood viscosity, plasma viscosity, but also triglyceride reducing.
Hirudo powder not only has the anabolic effect that improves prostaglandin, and is a kind of stronger thromboxane synthetic inhibitor, and can make PGI in the blood
2Rising TXB
2Descend.
Snake venom: during this thromboembolism preventing looses, used the microcrystalline Cellulose clathrate of agkistrodon halyx pallas venom, cobra venom.
Agkistrodon halys: warm, sweet, poisonous, function is dispeled the wind, analgesia.
Agkistrodon halyx pallas venom: agkistrodon halyx pallas venom has anticoagulant and thrombolytic depolymerization viscosity reduction, blood vessel dilating, microcirculation improvement effect, and its injection " Ahylysantinfarctase ", " Ahylysantinfarctase " are the good medicine that obtains the treatment thrombotic disease of the accurate font size of national drug.Agkistrodon halyx pallas venom is oral, its anticoagulant composition can absorb, when Chinese Medical Sciences University releives peptide enhancing peptide in purification from agkistrodon halyx pallas venom, after carrying out the separation of post layer, proved part enzyme in the agkistrodon halyx pallas venom once more, be to keep that it is active under the gastric acid condition, and when state's rabbit experimental lung plug, agkistrodon halyx pallas venom have thrombolytic effect.
Naja: warm, sweet, salty; Poisonous.Expelling wind and activating blood circulation is arranged, the meridian dredging, the bone and muscle strengthening effect, cobra venom contains phospholipase A, and haemolysis is arranged, and can prolong the clotting time of testing animal.
Adjuvant: Tuo tea, Herb Gynostemmae Pentaphylli-heat-clearing and toxic substances removing, tonifying QI to produce body fluid; Blood fat reducing, blood viscosity lowering.
Tuo tea: cold nature, bitter in the mouth, nontoxic
State-run health of France and Institute for Medical Research repeatedly clinical trial find, the Chinese yunnan Tuo tea has the blood fat reducing function, through 20 patients that lipids contents is high, drink one glass of Tuo tea water test every day, after two months, the average rate and blood-lipid decreased 22% of these patients, think through experiment: enhance metabolism balance and restraining cholesterol of Folium Camelliae sinensis has special effect, and thinking of also having drunk tea can control of diabetes.
Herb Gynostemmae Pentaphylli: the property hardship, be slightly cold, nontoxic.Heat-clearing and toxic substances removing, tonifying QI to produce body fluid, spleen-benefiting mind-tranquilizing, Herb Gynostemmae Pentaphylli energy blood fat reducing, the anti-platelet aggregation effect is the ideal medicament for the treatment of arteriosclerosis, coronary heart disease, cerebral ischemia clinically.
Adjuvant drug: Ganoderma, the Radix Astragali-QI invigorating, the consolidating superficial resistance coordinating the actions of various ingredients in a prescription of promoting blood circulation that nourishes heart, balance enhances metabolism.
Ganoderma: the life that is referred to as meaning " medicine-feeding " foster king in the Chinese ancient medicine book Shennong's Herbal is main, the medicine that is equivalent to the sky, outside the multiple functions such as the anti-curing cancers of Ganoderma decapacitation, the effect that the clean blood that purifies the blood is still arranged, blood viscosity lowering makes each venation event of unblocked blood flowing can remove blood stasis, root out thrombosis.
But take the Ganoderma life prolonging, but and coordinating the actions of various ingredients in a prescription, modern medicine study proves, the Ganoderma balance that can enhance metabolism has significant curative effect to many difficult and complicated illness.
The Radix Astragali: sweet, warm, return lung, spleen channel, the function invigorating QI to consolidate the body surface resistance, nourish heart promote blood circulation, in strengthening the body resistance, coordinating the actions of various ingredients in a prescription, can control that the motive is deficient, the disease of treatment blood-vessel obstructive.
Modern pharmacology confirms that the Radix Astragali has blood vessel dilating, and the protection erythrocyte deformability reduces platelet adhesion rate and reduces thrombosis.
Hirudo and snake venom are all poisonous in this prescription, and blood circulation promoting and blood stasis dispelling, can hinder healthy energy, select Ganoderma, the Radix Astragali for use for this reason, and not only two medicines all have the good curing effect to high blood viscosity, thrombotic disease, and main is coordinating the actions of various ingredients in a prescription, set upright and consolidate.
The present invention is a kind of antithrombotic Chinese powder medicine, through clinical practice 17 years, and in the medical research unit of family cooperation more than 10, treatment cerebral thrombosis 2300 many cases, curative effect is satisfied, and medication is more than 2 months, 550 examples that data is more complete.
Criterion of therapeutical effect:
Recovery from illness: symptom and Signs disappear substantially.
Produce effects: the paralyzed limbs muscular strength improves more than the II level, or language, dysphagia etc. obviously improve.
Take a turn for the better: the paralyzed limbs muscular strength improves more than the I level, or improvement such as language, dysphagia.
Invalid: the symptom Signs does not have improvement.
Therapeutic evaluation: 550 routine curative effect statistics
Recovery from illness: 253 examples account for 44.5%; Produce effects 163 examples account for 29.2%.
Take a turn for the better: 77 examples account for 13.7%; Invalid 65 examples account for 11.6%
Total effective rate 88.4%
Instructions of taking: 3 times on the one, a 3.3g, 30 minutes ante cibum are oral, forbid in hemorrhage, spitting of blood, hematemesis, and person within the internal organs major operation one month avoids clothes Semen phaseoli radiati, Radix Glycyrrhizae.
Advantages such as this preparation method of Chinese medicine of the present invention has science, and is easy to operate can fully be extracted the effective ingredient in the medicine, concentrate, and help taking and treating of thrombotic disease patient.
Embodiment 1:
A. get living drying in the sun Hirudo 20kg, wear into fine powder.
B. agkistrodon halyx pallas venom and each 20g of cobra venom and 9.96kg microcrystalline Cellulose are ground jointly, make the 10kg clathrate.
C. get red ganoderma in entity 100kg, add 1000kg water, at 90-100 ℃, two atmospheric pressure extracted the extract first pass 3 hours following minute three times, poured out extract, added water 1000kg again, second time 2 hours, pour out extract, add water 1000kg again, through 1 hour, pour out extract again, can be by being spray dried to smart powder, also but evaporation drying becomes smart powder, in leaching process, make the smart powder of 5kg by the 100kg raw material, dose the intoxicated powder of dextrose in right amount.
D. with Tuo tea, Herb Gynostemmae Pentaphylli, each 100kg of the Radix Astragali,, reach under two atmospheric pressure, add 1000kg water, divide and extract extract twice respectively at 90-100 ℃.First pass 2 hours, second time 1 hour, in making smart powder process, add a small amount of dextran powder, by spray drying or evaporation, make the smart powder of 5kg respectively.
E. encapsulate behind the smart powder 13kg of the trematodiasis of fetching water respectively, snake venom clathrate 15kg, the smart powder 10kg of Ganoderma, Radix Astragali essenc powder 10kg, the smart powder 25kg of Tuo tea, the clear powder 27kg of the Herb Gynostemmae Pentaphylli mix homogeneously
Embodiment 2:
Each step of a-d is identical with above-mentioned example, and the smart powder 15kg of water intaking trematodiasis, snake venom clathrate 13kg, the smart powder 12.5kg of Ganoderma, Radix Astragali essenc powder 7.5kg, the smart powder 27kg of Tuo tea, strand Lenzin powder 25kg encapsulate behind the mix homogeneously during batching.
Claims (2)
1. an antithrombotic Chinese powder medicine is characterized in that: form (percentage by weight) by following each set of dispense ratio
Hirudo powder 13-15%
Snake venom microcrystalline Cellulose clathrate 13-15%
The smart powder 10-12.5% of red ganoderma sporophore
Radix Astragali essenc powder 7.5-10%
The smart powder 25-27% of Tuo tea
Strand Lenzin powder 25-27%
2. the preparation method of an antithrombotic Chinese powder medicine, it is characterized in that: this preparation method is as follows:
A. will give birth to the drying in the sun Hirudo and wear into fine powder;
B. agkistrodon halyx pallas venom, cobra venom and microcrystalline Cellulose are ground jointly, make the enclose powder;
C. with the red ganoderma sporophore, at 90-100 ℃, two atmospheric pressure extract extract following minute three times, and 3 hours for the first time, 2 hours for the second time, 1 hour for the third time, add the water of 10 times of doses at every turn, add a small amount of dextran powder then and extract smart powder;
D. with the Radix Astragali, Tuo tea, Herb Gynostemmae Pentaphylli respectively at 90-100 ℃, following minute second extraction extract of two atmospheric pressure, 2 hours for the first time, 1 hour for the second time, add the water of 10 times of doses at every turn, add a small amount of dextran powder then and extract smart powder;
E. the batching that the a-d technological process is made mixes in proportion encapsulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01123530 CN1183928C (en) | 2001-07-30 | 2001-07-30 | Chinese medicine powder preparation for resisting thrombosis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01123530 CN1183928C (en) | 2001-07-30 | 2001-07-30 | Chinese medicine powder preparation for resisting thrombosis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1399976A true CN1399976A (en) | 2003-03-05 |
| CN1183928C CN1183928C (en) | 2005-01-12 |
Family
ID=4665132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01123530 Expired - Fee Related CN1183928C (en) | 2001-07-30 | 2001-07-30 | Chinese medicine powder preparation for resisting thrombosis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1183928C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804175A (en) * | 2010-03-10 | 2010-08-18 | 滕树财 | Anti-cancer Chinese medicinal powder and preparation method thereof |
| CN101810768A (en) * | 2010-03-10 | 2010-08-25 | 滕树财 | Antithrombotic Chinese medicinal powder and preparation method thereof |
-
2001
- 2001-07-30 CN CN 01123530 patent/CN1183928C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804175A (en) * | 2010-03-10 | 2010-08-18 | 滕树财 | Anti-cancer Chinese medicinal powder and preparation method thereof |
| CN101810768A (en) * | 2010-03-10 | 2010-08-25 | 滕树财 | Antithrombotic Chinese medicinal powder and preparation method thereof |
| CN101804175B (en) * | 2010-03-10 | 2011-11-30 | 滕树财 | Anti-cancer Chinese medicinal powder and preparation method thereof |
| CN101810768B (en) * | 2010-03-10 | 2012-12-05 | 滕树财 | Antithrombotic Chinese medicinal powder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1183928C (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1224691C (en) | Medical wine for invigorating vital function of kidney and its preparing process | |
| CN1580227A (en) | Doukey-hide gelatin-ginseng-radix astragali wine | |
| CN1091609C (en) | Tincture for treating rheumatoid arthritis and its preparing process | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN101156920B (en) | Oral administration and externally used drug for treating traumatic injury and its preparation method | |
| CN1232266C (en) | Chinese medicinal capsules for apoplexy and thoracic palsy and preparation thereof | |
| CN1183928C (en) | Chinese medicine powder preparation for resisting thrombosis and its preparation method | |
| CN1418696A (en) | Traditional Chinese medicine prepn. for treating cervical vertebra disease | |
| CN1283485A (en) | Instant particles 'Xinnaotong' for treating heart and brain diseases | |
| CN101810768B (en) | Antithrombotic Chinese medicinal powder and preparation method thereof | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1053111C (en) | Chinese medical composite preparation with such functions as dispelling toxicity, detoxicating, recuperating, health preserving and face nursing | |
| CN101181463B (en) | Chinese medicine composition for treating diabetes and method for preparing the same | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN1299718C (en) | Medicine for treating cardio-cerebral vascular disease and its preparing method | |
| CN1293891C (en) | Oteoporosis treating medicinal capsule and its preparation method | |
| CN1241632C (en) | Chinese patent medicine for treating cardiac function failure and its preparation method | |
| CN102988477A (en) | Black fungus capsule | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN1290554C (en) | Medicine used for tonifying-kidney strengthening-yang and replenishing-qi to invigorate the spleen, and its prepn. method | |
| CN101112494B (en) | Medicine for treating coronary disease and method for preparing the same | |
| CN1864728A (en) | Prescription and preparation method of yin-nourishing capsule containing ginseng and astragalus root | |
| CN1846739A (en) | Hemiplegia treating Chinese medicine composition and its prepn process | |
| CN101239149A (en) | Orally-taken Chinese medicinal composition for treating diabetes | |
| CN1062745C (en) | Shuangshi Zaishengjing oral liquor and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |